Skip to main content

Table 1 Summary of reported cases of patients undergoing MPP

From: Middle-preserving pancreatectomy: report of two cases and review of the literature

First author/year

Type of MPP

Patient age/gender

Number of lesion

Location of lesions

Lesion pathology

Specific surgical interventiond/Reconstruction A, B, C,D

Preserved length of pancreas

Post operative morbidity

Post operative endocrine insufficiency

Post operative exocrine insufficiency

Follow up (months)

Siassi/1999[4]

two

62/F

2

body/tail

PDAC/PDAC

atypical PPPD/ atypical LPeg/B

5 cm

no

yes

yes

NED (12)

Lloyd/2003[5]

one

31/F

2

head/body/tail

SPN/SPN

PPPD/ atypical LPe/D

2 cm

pseudocyst intervention

no

no

NED (17)

Miura/2007[1]

two

66/M

2

head/tail

bIPMN (adenoma)/PDAC

PD g/ atypical LPe/A

4 cm

no

no

no

NED (20)

 

two

66/M

2

head/tail

Vater carcinoma/IPMN (adenoma)

PPPD/ atypical LPfg/A

5 cm

no

no

no

NED (10)

one

70/M

2

head/tail

Vater carcinoma/ bIPMN (adenoma)

PPPD/ atypical LPe/A

6 cm

grade B PF

noa

no

NED (6)

Partelli/2009[6]

one

28

3M/2F

3

head/tail

NF-PET /NF-PET

4PPPD,1PD/5 atypical LPe/A

NA

1 patient grade A PF

no

yes

NED (118)

 

one

32

2

head/tail

NF-PET (carcinoma)/ NF-PET (carcinoma)

NA

no

no

NED (22)

 

one

70

5

head/tail

bIPMN/bIPMN

NA

yes

yes

NED (20)

 

one

35

2

head/tail

bIPMN/CP

NA

no

no

NED (18)

 

one

60

2

head/tail

retention cyst/CP

NA

yes

yes

NED (14)

Chiang/2009[7]

one

72/M

3

head/body/tail

mixIPMN (cancer in situ )/bIPMN /bIPMN (atypia)

extended PD/ atypical LPe/D

7 cm

no

noa

no

NED (36)

Kitasato/2010[8]

one

65/F

4

head/body/tail

Metastatic RCC/Metastatic RCC

IPHR/ atypical LPe/D

40% volume

no

no

no

NED (31)

Ohzato/2010[9]

one

67/F

5

head/body/tail

Metastatic RCC/ Metastatic RCC

atypical PPPD/atypical LPe/B

NA

bleeding reoperation

yes

no

NED (30)

Sperti/2010[10]

one

59/M

2

head/tail

mixIPMN (borderline)/CP

PPPD/atypical LPf/A

5cm

bleeding intervention

yes

yes

NED (11)

Chen/2011[11]

one

62/F

2

head/tail

Vater carcinoma/SPN

PD/ atypical LPe/D

NA

no

no

no

NED (6)

Horiguchi/2011[12]

one

69/M

2

head/tail

bIPMN (adenoma)/bIPMN (adenoma)

IPHR/ atypical LPe/D

NA

grade B PF

no

no

Deadh (16)

 

one

67/F

5

head/tail

Gastrinoma/Gastrinoma

DPPHR/ atypical LPf/A

5 cm

grade B PF

no

no

NED (77)

 

one

69/M

2

head/tail

bIPMN (adenoma)/bIPMN (adenoma)

IPHR/ atypical LPf/A

NA

grade B PF

yesac

no

NED (14)

 

one

83/F

2

head/tail

Bile duct cancer/bIPMN (adenoma)

SSPD/ atypical LPf/A

7 cm

no

no

no

NED (7)

Otani/2011[13]

one

77/M

2

head/tail

bIPMN(adenoma)/mainIPMN(adenoma)

PPPD/ atypical LPf/C

6 cm

no

noab

noab

NED (84)

Ours

one

24/F

2

head/tail

SPN/SPN

atypical PD/ atypical LPe/A

6 cm

no

yes

yes

NED (36)

 

one

36/F

2

head/tail

SCN/SCN

PD/ atypical LPf/B

5 cm

grade A DGE

no

no

NED (6)

  1. CP, chronic pancreatitis; DGE, delayed gastric emptying; DPPHR, duodenum-preserving pancreatic head resection; IPHR, inferior pancreatic head resection; IPMN, intraductal papillary mucinous neoplasm; bIPMN, branch duct IPMN; mixIPMN, mix duct IPMN; mainIPMN, main duct IPMN; LP, left pancreatectomy; MPP, middle-preserving pancreatectomy; NA, not available; NED, no evidence of disease; NF-PET, nonfunctioning pancreatic endocrine tumor; one, one-stage MPP; PD, pancreaticoduodenectomy; PDAC, pancreatic duct adenocarcinoma; PPPD, pylorus-sparing pancreaticoduodenectomy; RCC, renal cell carcinoma; SCN, serous cystic neoplasm; SPN, solid pseudopapillary neoplasm; SSPD, substomach-preserving pancreaticoduodenectomy; two, two-stage MPP.
  2. Reconstruction A, B, C, D: A, end-to-side pancreaticojejunostomy; B, end-to-side, duct-to-mucosa pancreaticojejunostomy; C, pancreaticogastrostomy; D, not available.
  3. Postoperative endocrine insufficiency was defined as new-onset diabetes or preoperative insufficiency deteriorating. Postoperative exocrine insufficiency was defined as steatorrhea, weight loss requiring pancreatic enzymes supplementation, or preoperative insufficiency deteriorating. adiabetes or exocrine insufficiency existed preoperatively; bpreoperative insufficiency improved after operation; cpreoperative insufficiency deteriorated after operation.
  4. d(ewiths splenectomy and fwithout); gin two-stage MPP, this operation is the previous one; hdied of malignant lymphoma.
  5. No post-operative mortality occurred in any patient.